- |||||||||| Observational data, Journal: Sarcopenia in older people with multiple sclerosis: A cross-sectional study. (Pubmed Central) - Jan 29, 2025
The present study shows that the sarcopenia diagnosis in older pwMS is more sensitive when using a lower extremity test, underlined by the preferentially lower muscle mass and strength in older pwMS compared to HC. Hence, when evaluating sarcopenia in older pwMS the diagnostics test should rely on the lower extremity test.
- |||||||||| Clinical data, Journal, Adverse events: Psoas muscle gauge and adverse clinical outcomes in patients on hemodialysis. (Pubmed Central) - Jan 28, 2025
Psoas muscle gauge accurately predicted the risk of all-cause mortality and new cardiovascular events in patients undergoing hemodialysis. For predicting all-cause mortality, psoas muscle gauge may be recommended compared to psoas muscle index.
- |||||||||| etoposide IV / Generic mfg.
Journal: A Natural Autophagy Activator Castanea crenata Flower Alleviates Skeletal Muscle Ageing. (Pubmed Central) - Jan 28, 2025 It achieved this by modulating AMPK and EP300 acetyltransferase activity, with contributions from its constituents, ellagic acid and polyamines. These findings highlight the potential of CCFE as a therapeutic agent for extending healthspan and mitigating sarcopenia, providing a basis for future clinical trials.
- |||||||||| Journal: Small bites, big impact: The importance of evening snacks in patients with advanced chronic liver disease. (Pubmed Central) - Jan 28, 2025
In this randomised control trial, Yu et al demonstrated that long-term nocturnal snacks have the potential to significantly improve body composition by body fat mass, visceral fat area and body cell mass in patients with ACLD. While the improvement in skeletal muscle mass was minor, the promising results in other compositions provide hope for future research and patient care.
- |||||||||| Review, Journal: The role of chronic low-grade inflammation in the development of sarcopenia: Advances in molecular mechanisms. (Pubmed Central) - Jan 28, 2025
Herein, we explore the role of chroniclow-gradeinflammation in the development of sarcopenia and its underlying molecular mechanisms, including chronic inflammation-associated signaling pathways, immunosenescence, obesity and lipid infiltration, gut microbiota dysbiosis and intestinal barrier disruption, and the decline of satellite cells. The interplay and interaction of these molecular mechanisms provide new perspectives on the complexity of the pathogenesis of sarcopenia and offer a theoretical foundation for the development of future therapeutic strategies.
- |||||||||| Review, Journal: Proximal Junctional Kyphosis above Long Spinal Fusions. (Pubmed Central) - Jan 27, 2025
The best treatment is prevention, with a thorough analysis of risk factors leading to a well-planned and personalized surgery. Regular postoperative follow-up is essential.
- |||||||||| Acomplia (rimonabant) / Sanofi
Preclinical, Review, Journal: Impact of CB1 receptor antagonism on skeletal muscle hypertrophy and metabolic health: a systematic review of preclinical studies. (Pubmed Central) - Jan 27, 2025 From these, ten studies were selected, involving 338 rodents, using CB1 antagonists like rimonabant and AM251...This review proposes CB1 receptor antagonism as a promising approach for enhancing muscle hypertrophy and improving metabolic health, with potential applications in treating such conditions as obesity, type 2 diabetes, and sarcopenia. Future research should aim to standardize intervention protocols and explore integrated therapies to fully harness the benefits of CB1 modulation.
- |||||||||| Journal: Factors associated with sarcopenia in a population of non-disabled older patients. (Pubmed Central) - Jan 18, 2025
Regarding sleep duration, no SMM changes over time were seen in short sleepers, but findings were discordant in long sleepers: a reduction of SMM using bioimpedance, but no change using the formula. We could not confirm an association between sarcopenia and the metabolic syndrome, but with the obesity and hypertension components.
- |||||||||| Review, Journal: TLR/NLRP3 inflammasome signaling pathways as a main target in frailty, cachexia and sarcopenia. (Pubmed Central) - Jan 18, 2025
Modulating TLR/NLRP3 inflammasome pathways may also hold promise in slowing down the progression of sarcopenia, preserving muscle mass and enhancing overall functional ability in elderly people. The aim of this review is to investigate the signaling pathways of the TLR/NLRP3 inflammasome as a main target in frailty, cachexia and sarcopenia.
- |||||||||| Observational data, Journal: Related factors of sarcopenia risk in Chinese older people - a cross-sectional study. (Pubmed Central) - Jan 17, 2025
Level of education is the primary factor determining the risk of sarcopenia in older adults aged 60-69, while endowment insurance is the primary factor influencing the risk of sarcopenia in older adults aged 70-79. To prevent and intervene earlier in the beginning and progression of sarcopenia in the elderly, it is advised that knowledge of the condition be raised among the older population.
- |||||||||| Journal: Safe and Orally Bioavailable Inhibitor of Serine Palmitoyltransferase Improves Age-Related Sarcopenia. (Pubmed Central) - Jan 16, 2025
Mechanistic studies revealed that ALT-007 enhances protein homeostasis in Caenorhabditis elegans and mouse models of aging and age-related diseases, such as sarcopenia and inclusion body myositis (IBM); this effect is mediated by a specific reduction in very-long chain 1-deoxy-sphingolipid species, which accumulate in both muscle and brain tissues of aged mice and in muscle cells from IBM patients. These findings unveil a promising therapeutic avenue for developing safe ceramide inhibitors to address age-related neuromuscular diseases.
- |||||||||| Clinical data, Retrospective data, Review, Journal: Clinical outcome changes in sarcopenic obesity: a meta-analysis of exercise training methods. (Pubmed Central) - Jan 16, 2025
Compared to aerobic training, resistance training, and mixed training may offer more pronounced improvements, enhancing physical functioning in sarcopenic obesity patients. This underscores the clinical significance of exercise intervention in treating muscle-reducing obesity, suggesting future studies explore exercise intervention's role and mechanism, particularly related to IGF-1, IL-6, and other cytokines.
|